Fig. 4: Kaplan–Meier curves of TP53m-BRCAwt population RFS from time of randomization.
Vigil demonstrates RFS advantage (HR = 0.44, p = 0.01) in the TP53m-BRCAwt population.
Fig. 4: Kaplan–Meier curves of TP53m-BRCAwt population RFS from time of randomization. | Cancer Gene Therapy
